Incyte Hits Pause on CSU Trial of MRGPRX2
Incyte is pausing enrollment in the ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the U.S. Food and Drug Administration (FDA), and Incyte will work closely with the FDA to determine next […]